ANNX - Annexon Inc

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.

52W High

$7.85

52W Low

$1.29

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.16

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.47

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.20

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.42%

Institutions (25–75% balanced)

100.22%

Shares Outstanding

109,887,000

Float

89,061,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.29

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.67%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0024

-0.0177

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 12, 2025